SmallCaps
ASX:IVXPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

Invion Ltd

$0.041
Day Range
$0.041 – $0.041
52 Week Range
$0.035 – $0.200
Volume
11.56K
Avg Volume (10D)
78.77K
Market Cap
$4.48M

Price Chart

OHLC · volume · moving averages

$0.041-$0.049 (-54.44%)over 6M
Hi$0.099Lo$0.035
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.041
Previous Close
$0.041
Day High
$0.041
Day Low
$0.041
52 Week High
$0.200
52 Week Low
$0.035

Valuation

Fundamental multiples

Market Cap
4.48M
Shares Outstanding
109.20M
Price to Book
0.62

Trading Activity

Volume & order book

Volume
11.56K
Value Traded
473.96
Bid
$0.041 × 1,552
Ask
$0.044 × 15,455

Performance

Returns across timeframes

1 Day
-4.65%
5 Day
-8.89%
13 Week
-46.05%
52 Week
-67.20%
YTD
-55.91%

Technical Indicators

Momentum & moving averages

RSI (14)
30.83
50-Day SMA
$0.054
200-Day SMA
$0.084

— From the desk

Latest News

Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial
Biotechnology

Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial

Invion (ASX: IVX) has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland. Data from a safety review committee (SRC) suggested that treatment with the novel photosensitiser was well-tolerated and feedback from clinicians […]

Weekly wrap: shares take a breather as Wall Street finds caution
Hot Topics

Weekly wrap: shares take a breather as Wall Street finds caution

Australia’s share market took a breather on Friday as Wall Street turned cautious about whether the Federal Reserve will continue to cut interest rates this month. By the close of trade the ASX 200 had dropped 0.6% or 54 points to 8420.9 points with only one of the 11 sectors closing up. The fall meant […]

Invion commences dosing in INV043 trial to treat non-melanoma skin cancer
Biotechnology

Invion commences dosing in INV043 trial to treat non-melanoma skin cancer

Clinical-stage life sciences company Invion (ASX: IVX) has dosed the first patient in its Phase I/II non-melanoma skin cancer (NMSC) trial using active pharmaceutical ingredient and lead candidate INV043. The trial will aim to evaluate the safety and efficacy of the topically applied INV043, a novel photosensitiser developed in Australia for use in photodynamic therapy […]

Weekly wrap: record close as investors bet on a soft landing
Hot Topics

Weekly wrap: record close as investors bet on a soft landing

Continuing optimism that the world economy is heading for a soft landing helped to push the Australian share market to a fresh record high to close the week. Despite some early indecision, the consensus on the US Federal Reserve’s bold move to cut a full 0.5% off official interest rates seems to be that it […]